Peramivir
Peramivir is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- FDA approved for uncomplicated influenza in patients 2 years and older with symptoms present less then 2 days.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Treatment of influenza for hospitalized adult and pediatric patients for whom therapy with an IV anti-influenza drug is needed.
- Limited data available to support efficacy in complicated influenza, or influenza requiring hospitalization or influenza > 48h duration[7].
- Peramivir can be considered for treatment failure occurring with use of currently approved anti-influenza drugs (e.g., oseltamivir and zanamivir) and in patients who are unable to take oral or inhaled anti-viral therapy.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- FDA approved for uncomplicated influenza in patients 2 years and older with symptoms present less then 2 days.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Treatment of influenza for hospitalized adult and pediatric patients for whom therapy with an IV anti-influenza drug is needed.
- Limited data available to support efficacy in complicated influenza, or influenza requiring hospitalization or influenza > 48h duration[7].
- Peramivir can be considered for treatment failure occurring with use of currently approved anti-influenza drugs (e.g., oseltamivir and zanamivir) and in patients who are unable to take oral or inhaled anti-viral therapy.
There's more to see -- the rest of this entry is available only to subscribers.